

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CD34 MicroBead Kit, human

RRID:AB_2848167

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-046-702, RRID:AB_2848167

Antibody Information

URL: http://antibodyregistry.org/AB_2848167

Proper Citation: Miltenyi Biotec Cat# 130-046-702, RRID:AB_2848167

Target Antigen: CD34

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 2021; Applications: Positive selection

Antibody Name: CD34 MicroBead Kit, human

Description: This monoclonal targets CD34

Target Organism: mouse

Clone ID: AC136

Antibody ID: AB_2848167

Vendor: Miltenyi Biotec

Catalog Number: 130-046-702

Record Creation Time: 20231110T032210+0000

Record Last Update: 20260828T230408+0000

Ratings and Alerts

No rating or validation information has been found for CD34 MicroBead Kit, human.

Warning: Discontinued: 2021

Discontinued: 2021; Applications: Positive selection

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Pak M, et al. (2026) Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi. *Cell genomics*, 6(1), 101036.

Kawamura S, et al. (2025) Modeling antithymocyte globulin-induced microvasculopathy using human iPSC-derived vascularized liver organoids. *Cell reports. Medicine*, 6(11), 102433.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. *International journal of molecular sciences*, 25(13).

Adnan Awad S, et al. (2024) Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. *Cell reports. Medicine*, 5(5), 101521.

Bruss C, et al. (2024) Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative - specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. *Frontiers in immunology*, 15, 1355130.

Watanuki S, et al. (2024) SDHAF1 confers metabolic resilience to aging hematopoietic stem cells by promoting mitochondrial ATP production. *Cell stem cell*, 31(8), 1145.

Lin C, et al. (2023) S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. *Cancer research communications*, 3(3), 420.

Kawakami E, et al. (2023) Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19. *Cell stem cell*, 30(10), 1315.

Cheong JG, et al. (2023) Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. *Cell*, 186(18), 3882.

Hormaechea-Agulla D, et al. (2021) Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN γ signaling. *Cell stem cell*, 28(8), 1428.

Reid JC, et al. (2021) Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. *Cell reports*, 34(11), 108845.

Richardson SE, et al. (2021) In vitro differentiation of human pluripotent stem cells into the B lineage using OP9-MS5 co-culture. STAR protocols, 2(2), 100420.

Liu X, et al. (2021) Distinct human Langerhans cell subsets orchestrate reciprocal functions and require different developmental regulation. Immunity, 54(10), 2305.

Gonzalez-Menendez P, et al. (2021) An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism. Cell reports, 34(5), 108723.

Frame JM, et al. (2020) Metabolic Regulation of Inflammasome Activity Controls Embryonic Hematopoietic Stem and Progenitor Cell Production. Developmental cell, 55(2), 133.